Global private equity and venture capital news and research

Posts Tagged ‘Novimmune’

18 February 2014

Rosetta Capital leads $66m Series B for Novimmune

drug-pharma-medical-healthcare London-based venture investor Rosetta Capital has led a CHF60m ($66m) Series B financing round for drug maker Novimmune.

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016